At DZD, we are developing a sequencing-based rapid diagnostic that identifies, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. Current approaches take 2-5 days to provide similar information, a time delay that is associated with an 8% increase in death per hour for severe infections. Our diagnostic will enable hospitals to reduce patient length of stay, the overuse of expensive and often ineffective antibiotics, and most importantly, excess mortality.
Our diagnostic technologies are focused on three major areas that work in tandem with commercially available whole genome sequencing technology:
Blood2Bac™ is a process for ultra-high enrichment of bacterial DNA that allows us to go from a clinical blood sample with a billion times more human DNA than bacterial DNA to a diagnostic readout that contains far more bacterial DNA sequencing data than human data.
Keynome® is our machine learning algorithm for predicting antibiotic resistance and susceptibility profiles directly from whole genome sequencing data. Unlike traditional “database look-up” approaches that identify the presence or absence of a limited set of well-known resistance genes, Keynome allows for the simultaneous testing of a comprehensive set of bacterial species and resistance markers, along with the ability to identify novel resistance determinants as they emerge.
MicrohmDB® is our large-scale, proprietary antimicrobial database that combines clinically relevant pathogen genomic sequences with their phenotypically derived resistance and susceptibility profiles. This dataset, one of the largest of its kind in the world, provides Day Zero with a unique ability to train our algorithm on an ever growing base of clinically relevant data.
Our focus at Day Zero Diagnostics is the integration of these technologies into a new class of diagnostic that can improve patient care and hospital economics.